Prader-Willi Syndrome Market to Expand by 2036 as New Therapeutic Opportunities Address Unmet Clinical Needs | DelveInsight
The Prader-Willi syndrome market is expected to grow steadily, driven by increasing disease awareness, improved diagnosis, and the development of novel targeted therapies such as WAKIX (Harmony Biosciences), ARD-101 (Aardvark Therapeutics), PBF-999 (Palobiofarma), CSTI-500 (ConSynance...
Covered in this story
What has happened since
- Pbf Energy Inc Class a is down 2.4% since this was published, 8 days ago.
- Aardvark Therapeutics Inc is down 12.4% since this was published, 8 days ago.
Price move measured from the close nearest publication to the latest quote.
Analyst targets on Pbf Energy Inc Class a
- BMO Capital Markets: $82.3 → $80 by Oct 2027 · Market Perform via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $PBF yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Pbf Energy Inc Class a →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.